Screener
AnaptysBio, Inc. ANAB Biopharma Company — Operating Income
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AnaptysBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219515
| Line item | Biopharma | Royalty Management | Total |
|---|---|---|---|
| Internal G&A(2) | 10,135 | 3,948 | 14,083 |
| Total G&A | 18,856 | 7,346 | 26,202 |
| Total operating expenses | 52,811 | 7,382 | 60,193 |
| (Loss) income from operations | (52,811) | 18,174 | (34,637) |
| Interest income | 2,328 | 325 | 2,653 |
| Non-cash interest expense | — | (20,859) | (20,859) |
| Other expense, net | (1) | — | (1) |
| Total other income (expense), net | 2,327 | (20,534) | (18,207) |
Item 1. Consolidated Financial Statements
FAQ
- What is AnaptysBio, Inc.'s biopharma company — operating income?
- AnaptysBio, Inc. (ANAB) reported biopharma company — operating income of -$52.81M in Q1 2026.
- How has AnaptysBio, Inc.'s biopharma company — operating income changed year-over-year?
- AnaptysBio, Inc.'s biopharma company — operating income decreased by 3.0% year-over-year, from -$51.28M to -$52.81M.
- What does biopharma company — operating income mean?
- This metric measures the profitability of the company's core operations by subtracting total operating expenses from revenue. For clinical-stage biopharma companies, this is typically negative, reflecting significant investment in pipeline development before commercialization. It serves as a key indicator of the company's operational financial health and the extent of its reliance on external financing.
Ask your AI about AnaptysBio, Inc.'s biopharma company — operating income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude